• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore , Nov. 8

Advinus Therapeutics, the Tata-backed drug research and contract services company, has announced a tie-up with Veeda Clinical Research to provide seamless pre-clinical and early clinical development through phase II.

The alliance covers pre-clinical and early clinical development, animal and human safety pharmacology, pre-clinical toxicology and pharmacology, clinical pharmacology as also microdosing capabilities to pick drug candidates on the basis of human `PK' data, an Advinus release here said.

Advinus is a venture between the Tata Group and Dr Rashmi Barbhaiya, former research head at Ranbaxy Labs.

Veeda Clinical Research is a contract research organisation with clinical pharmacology units in the UK and in Ahmedabad.

The tie-up will set a trend in the emerging drug discovery industry in the country and will attract companies looking for pre-clinical and clinical services in Europe and the Americas, the release said.

The existing clients of both companies will also be able to tap the integrated pre-clinical and early clinical development capabilities of the alliance.

Dr Barbhaiya, Advinus CEO and Managing Director, said, "Our alliance offers seamless access to our combined capabilities in pre-clinical and early clinical development of drug candidates to our clients. (It) represents an important milestone in our strategy to offer integrated R&D services to our partners."

According to Dr Apoorva Shah, Managing Director, Veeda CR, this would give it access to Advinus's pre-clinical and pharmaceutical development capabilities.

"Our combined capabilities will offer unique opportunities for developing investigative new drugs and for early clinical development to our clients in a seamless manner."

More Stories on : Alliances & Joint Ventures | Medical Institutions & Hospitals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Vectra to invest $61 m in Tatra plants' revamp

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line